EClinCloud Named to the Top 5 Most Investable Companies in the Digital Economy

Author: EClinCloud. Originally published on the EClinCloud WeChat official account on July 31, 2026.
Recently, the results of the 12th "Search for Ningbo's Most Investable Companies" selection were officially announced. EClinCloud stood out from more than 620 participating companies to be named among the Top 5 Most Investable Companies in the "Digital Economy" category. At the same time, the company's founder and CEO, Dr. Qin Long, received the "Entrepreneurial Pioneer" individual award, making EClinCloud a dual winner in this year's selection.
Innovation Capability and Commercial Value Recognized
Now in its twelfth edition, the "Search for Ningbo's Most Investable Companies" program is one of the most influential venture capital events in the Ningbo region. Guided by multiple government authorities including the Ningbo Municipal Local Financial Supervision and Administration Bureau, the Ningbo State-owned Assets Supervision and Administration Commission (SASAC), and the Ningbo Office of the China Banking and Insurance Regulatory Commission (CBIRC), the event aims to identify high-quality local Ningbo enterprises with strong growth potential and investment value and to build a bridge connecting industry and capital.
Centered on the theme of technology- and innovation-driven leadership and focused on new quality productive forces, the program covered emerging industry tracks such as intelligent manufacturing, artificial intelligence, the digital economy, and green and low-carbon development, attracting applications from more than 620 companies since its launch in March. Spanning several months and multiple rounds of screening, the selection process conducted a comprehensive, multi-dimensional evaluation of participating companies across innovation capability, growth potential, team strength, business model, and industry outlook.
EClinCloud stood out from the broad pool of applicants to rank among the top five in the digital economy category, reflecting strong recognition of its overall capabilities—including innovation and commercial value—as well as confidence in its future growth potential.
As an AI technology company in clinical research, EClinCloud remains committed to independent innovation. Across the full clinical trial lifecycle, it continues to advance the R&D and application of frontier technologies—including artificial intelligence, big data, and cloud computing—building a product portfolio that spans core operational scenarios such as data capture, project management, endpoint assessment, data governance, and intelligent analytics to provide global pharmaceutical and medical device companies, CROs, and research institutions with more intelligent, reliable, and compliant digital solutions.
EClinCloud will continue to strengthen its recruitment and development of AI talent, deepen the innovative application of AI across clinical research scenarios, accelerate its global expansion, and further build an integrated innovation system uniting technology, products, and services to create value for the high-quality advancement of clinical research.
EClinCloud's AI-Driven Product and Service Portfolio
- eCOA
- CTMS
- eTMF
- EDC
- RTSM
- RM
- IRC
- eLearning
- Scale management
- Rater training
About EClinCloud
EClinCloud is a leading AI company in the clinical research industry. Powered by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products—including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM—as well as scale management, linguistic validation, rater training, and data quality analysis services to deliver efficient and accurate digital solutions. Leveraging AI predictive models and an intelligent data platform, EClinCloud dynamically assesses and helps improve the success rate of drug clinical trials, helping shorten drug and medical device R&D cycles to benefit patients.



